Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study

Genovese Mark; Kremer Joel; Zamani Omid; Ludivico Charles; Krogulec Marek; Xie Li; Beattie Scott; Koch Alisa; Cardillo Tracy; Rooney Terence; Macias William; Schlichting Douglas; Smolen Josef; Bookman Arthur

首页> 外文期刊>The Journal of rheumatology >Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study

【24h】

Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study

机译：Baricitinib，口腔janus激酶（Jak）1 / JAK2抑制剂，有活性类风湿性关节炎（RA）和对TNF抑制剂的不足反应不足：第3阶段RA-BEACON研究的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of rheumatology》 |2016年第6期|共1页
作者
Genovese Mark; Kremer Joel; Zamani Omid; Ludivico Charles; Krogulec Marek; Xie Li; Beattie Scott; Koch Alisa; Cardillo Tracy; Rooney Terence; Macias William; Schlichting Douglas; Smolen Josef; Bookman Arthur;
展开▼
作者单位

Stanford Univ Med Ctr Palo Alto CA 94304 USA;

Albany Med Coll Albany NY 12208 USA;

Rheumazentrum Favoriten Vienna Austria;

East Penn Rheumatol Associates Bethlehem PA USA;

MAK MED Rheumatol Clin Nadarzyn Poland;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Med Univ Vienna Vienna Austria;

Univ Toronto Toronto ON Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study [J] . Genovese Mark, Kremer Joel, Zamani Omid, The Journal of rheumatology . 2016,第6期

机译：活动性类风湿关节炎（RA）患者和对TNF抑制剂反应不足的患者口服Barustinib（JAK）1 / JAK2抑制剂：3期RA-BEACON研究的结果
2. Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study [J] . Dougados Maxime, van der Heijde Desiree, Chen Ying-Chou, The Journal of rheumatology . 2016,第6期

机译：活动性类风湿关节炎（RA）和对cDMARD治疗反应不足的患者中的口服Janus激酶（JAK）1 / JAK2抑制剂Baricitinib：3期RA-BUILD研究的结果
3. Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study [J] . Dougados Maxime, van der Heijde Desiree, Chen Ying-Chou, The Journal of rheumatology . 2016,第6期

机译：Baricitinib，口腔janus激酶（Jak）1 / JAK2抑制剂，有活性类风湿性关节炎（RA）和对CDMARD治疗的不充分反应：第3阶段RA-BUILD研究的结果
4. Development of TNF-alpha Inhibitor Drugs in Treatment of Rheumatoid Arthritis [C] . Dong Jin-rui, He Ming-hao, Han Mo, Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：TNF-α抑制剂在类风湿关节炎治疗中的应用
5. Transcriptional and Proteomic Changes Associated with the Sensitivity and Resistance to JAK2 Inhibitors: Implications for the Treatment of BCR-ABL (-) Myeloproliferative Neoplasms (MPNs). [D] . McDevitt, Theresa Marie. 2012

机译：与JAK2抑制剂的敏感性和抗性相关的转录和蛋白质组学变化：对BCR-ABL（-）骨髓增生性肿瘤（MPNs）的治疗意义。
6. Extended report: Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON) [O] . Josef S Smolen, Joel M Kremer, Carol L Gaich, -1

机译：扩展报告：巴雷替尼在类风湿性关节炎患者中进行的随机III期研究的患者报告结果且对生物制剂的反应不足（RA-BEACON）
7. A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–TNF Therapy [O] . Kremer, JM, Emery, P, Camp, HS, 2016

机译：aBT-494（一种选择性JaK1抑制剂）在类风湿性关节炎患者和抗TNF治疗反应不足的相2b研究

Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study

著录项

相似文献

相关主题

期刊订阅